Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Congenital Hyperinsulinism Market" report has been added to ResearchAndMarkets.com's offering. The congenital hyperinsulinism market has demonstrated ...

Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five ...

"FDA's granting of Orphan Drug Designation is a recognition of the serious unmet need patients with tumor hyperinsulinism face and validates the potential significant benefit that ersodetug can ...

Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

To participate in the study, please visit www.rawoodfoundation.org/hptumorregistry to enroll into the Hypothalamic-Pituitary Brain Tumors Patient Registry and complete the available surveys. For those ...

After hours: March 20 at 6:19:09 PM EDT Loading Chart for RZLT ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...